A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

NCT05144529 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Slow enrollment.

Conditions

Lung Cancer Metastatic

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Evolocumab

Sponsor

Eziafa Oduah, MD, PhD, MPH